Evaluation of survival and imaging findings in cholangiocarcinoma patients who undergo multimodalitytherapy

Evaluation of survival and imaging findings in cholangiocarcinoma patients who undergo multimodalitytherapy (drainage,brachytherapy,external radiotherapy and chemotherapy )

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201201227435N1

Enrollment

Registered

2012-05-17

Start date

2012-06-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cholangiocarcinoma. Biliary tract, unspecified

Interventions

An experienced liver and billiary tract interventional radiologist will place an internal-external drainage catheter in billiary tract,at the stenosis site. A radiotherapist will place the source of

Treatment - Other

An experienced liver and billiary tract interventional radiologist will place an internal-external drainage catheter in billiary tract,at the stenosis site. A radiotherapist will place the source o

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion:Unresectable nonmetastatic extrahepatic cholangiocarcinoma Patients who have informed consent Exclusion:Serious cardiac,renal and pulmonary disease in later 6 month Karnofsky performance status <70

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Survival. Timepoint: Till 2 years after intervention. Method of measurement: Surviving monthes of patient's life.;Symptom free period. Timepoint: Every 3 monthes till two years. Method of measurement: Physical examination(icter,itching), boichemical laboratory data.;Biliary tracts caliber. Timepoint: Every 3 months till 2 years. Method of measurement: Sonographic examination.	—

Secondary

Measure	Time frame
CA19-9 after intervantion. Timepoint: Every 3 months till 2 years. Method of measurement: Laboratory tests.;Liver function tests after intervention. Timepoint: Every 3 months till 2 years(AST,ALT,ALP). Method of measurement: Laboratory tests.;Cholangitis. Timepoint: Every 3 months till 2 years. Method of measurement: Physical examination, serum billirubin level.;Gastrodudenitis. Timepoint: Until the end of radiotherapy period. Method of measurement: Questionnare.	—

Measure

Time frame

CA19-9 after intervantion. Timepoint: Every 3 months till 2 years. Method of measurement: Laboratory tests.;Liver function tests after intervention. Timepoint: Every 3 months till 2 years(AST,ALT,ALP). Method of measurement: Laboratory tests.;Cholangitis. Timepoint: Every 3 months till 2 years. Method of measurement: Physical examination, serum billirubin level.;Gastrodudenitis. Timepoint: Until the end of radiotherapy period. Method of measurement: Questionnare.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hazhir Saberi

Radiology department of Tehran university of medical sciences

hazhir_saberi@hotmail.com+98 21 6658 1577

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026